drugset / Trial / NCT00226395

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

NCT00226395

Phase 3 Completed 320 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the analgesic efficacy and safety of two doses of oxymorphone immediate release (IR) compared to placebo and oxycodone in post-surgical pain.

Timeline

Start
2004-09
Primary completion
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymorphone Small molecule 10 mg
Subject Oxymorphone Small molecule 20 mg

Indications

No indication recorded.